Loading…
MaxCyte, Inc. is projected to rise to $1.19 by 2027, a +13% move from its current price of $1.05. MXCT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $1.02 | $1.05 | $1.09 | +0.05% |
| Aug 5 | $1.00 | $1.05 | $1.10 | +0.10% |
| Aug 6 | $0.992 | $1.05 | $1.11 | +0.15% |
| Aug 7 | $0.9836 | $1.05 | $1.13 | +0.20% |
| Aug 8 | $0.9763 | $1.05 | $1.13 | +0.26% |
| Aug 9 | $0.9699 | $1.05 | $1.14 | +0.31% |
| Aug 10 | $0.964 | $1.05 | $1.15 | +0.36% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.964 | $1.05 | $1.15 | +0.36% |
| Week 2 | $0.9324 | $1.06 | $1.20 | +0.72% |
| Week 3 | $0.9096 | $1.06 | $1.24 | +1.08% |
| Week 4 | $0.8913 | $1.07 | $1.27 | +1.44% |
| Week 5 | $0.8759 | $1.07 | $1.30 | +1.81% |
| Week 6 | $0.8625 | $1.07 | $1.33 | +2.17% |
| Week 7 | $0.8506 | $1.08 | $1.36 | +2.54% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
MaxCyte, Inc. is a life sciences company that discovers, develops, and commercializes cell therapeutics in the United States and internationally. Its product lineup includes ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation tool for protein production and drug development, and for expressing therapeutic targets in cell-based assays; ExPERT GTx, a flow electroporation system for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
The company also provides disposable processing assemblies to process and electroporate cells, along with accessories such as electroporation buffer solutions and software protocols.
MaxCyte licenses and sells its instruments and technology, and sells its consumables to developers of cell therapies as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. It has a strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc.
was incorporated in 1998 and is headquartered in Rockville, Maryland.
MaxCyte, Inc. (MXCT) operates in the Healthcare sector as a life sciences company focused on cell therapeutics. It is currently trading with a price of $1.02 and a market capitalization of $109.26M, and it holds a rank of 3981.
The current price and market position place it among smaller-cap healthcare names. The forecasted price trajectory shows a path from a near-term steady level toward higher levels in the longer term, with notable upside projected in the 2030s and beyond. Overall, the outlook suggests potential appreciation from the current level, driven by forward-looking estimates across multiple years.
A major floor 35.6% below — a decisive break under it would weaken the trend.
The nearest floor, 3.8% below — buyers have tended to step in here.
The nearest ceiling, 35.2% above — a clean break opens room to run.
A major ceiling 49.5% above — clearing it would confirm fresh momentum.
Key MXCT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MXCT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.04 | Buy | $1.06 | Sell |
| MA 10 | $1.09 | Sell | $1.10 | Sell |
| MA 20 | $1.21 | Sell | $1.15 | Sell |
| MA 50 | $1.18 | Sell | $1.14 | Sell |
| MA 100 | $1.00 | Buy | $1.11 | Sell |
| MA 200 | $1.17 | Sell | $1.28 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.15 | Neutral |
| Stoch RSI (14) | 12.91 | Buy |
| CCI (20) | -89.00 | Neutral |
| Williams %R (14) | -90.24 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -26.06 | Sell |
| Bollinger %B (20,2) | 0.20 | Neutral |
| Stochastic %K (14) | 9.76 | Buy |
| TRIX (15) | -0.17 | Sell |
| Awesome (5,34) | -0.17 | Sell |
| Ultimate (7,14,28) | 30.86 | Neutral |
| Momentum (10) | -0.19 | Sell |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 1.01 | Buy |
| ADX (14) | 23.86 | Sell |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is NEUTRAL, with RSI14 at 30, indicating modest momentum. The stock’s 50-day and 200-day simple moving averages are both $1.18, providing a near-term reference for support around the current price.
Near-term support sits at $1.02 and resistance at $1.42, framing a 30-day range from $0.7899 to $1.32. These levels suggest limited near-term upside relative to the current price, with volatility typical for a small-cap healthcare name.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.676 | $1.05 | $1.35 | 0% | Neutral | |
| $0.9288 | $1.19 | $1.62 | +13% | Neutral | |
| $0.8638 | $1.15 | $1.64 | +9% | Neutral | |
| $0.9045 | $1.24 | $1.83 | +18% | Neutral | |
| $1.02 | $1.43 | $2.18 | +36% | Bullish | |
| $1.07 | $1.54 | $2.40 | +47% | Bullish | |
| $1.33 | $1.95 | $3.11 | +86% | Bullish | |
| $1.45 | $2.18 | $3.54 | +107% | Bullish | |
| $1.33 | $2.04 | $3.39 | +95% | Bullish | |
| $1.38 | $2.15 | $3.63 | +105% | Bullish | |
| $1.99 | $3.41 | $6.18 | +225% | Bullish | |
| $2.72 | $5.45 | $10.94 | +419% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.676 | $1.05 | $1.27 | +0.00% |
| September 2026 | $0.9186 | $1.09 | $1.34 | +4.17% |
| October 2026 | $0.9162 | $1.10 | $1.37 | +0.58% |
| November 2026 | $0.8795 | $1.06 | $1.34 | -3.34% |
| December 2026 | $0.8755 | $1.07 | $1.35 | +0.18% |
Click any year to see its month-by-month MXCT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MXCT is projected to trade between $0.676 and $1.35, averaging $1.05 — a potential gain of 0% from today's $1.05. A consolidation phase looks the most probable path here.
MaxCyte, Inc.'s 2027 outlook centres on $1.19, within a $0.9288 to $1.62 range. That is up +13% on the projected 2026 average. That marks a +13% change versus current levels. Price action looks broadly range-bound.
By 2028, MXCT could reach as high as $1.64, with a base case around $1.15 and support toward $0.8638 — roughly +9% from $1.05. A consolidation phase looks the most probable path here.
Expect MXCT to range from $0.9045 to $1.83 through 2029. The $1.24 average target implies a +18% move from current prices. That is up +8% on the projected 2028 average. Price action looks broadly range-bound.
The MXCT price prediction for 2030 points to an average of $1.43 (low $1.02, high $2.18) — a potential gain of +36% on today's $1.05. Buyers look set to stay in control over this stretch.
In 2031, MXCT is projected to trade between $1.07 and $2.40, averaging $1.54 — a potential gain of +47% from today's $1.05. That is up +8% on the projected 2030 average. Momentum favours further upside here.
MaxCyte, Inc.'s 2032 outlook centres on $1.95, within a $1.33 to $3.11 range. That is up +27% on the projected 2031 average. That marks a +86% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, MXCT could reach as high as $3.54, with a base case around $2.18 and support toward $1.45 — roughly +107% from $1.05. Momentum favours further upside here.
Expect MXCT to range from $1.33 to $3.39 through 2034. The $2.04 average target implies a +95% move from current prices. That is -6% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The MXCT price prediction for 2035 points to an average of $2.15 (low $1.38, high $3.63) — a potential gain of +105% on today's $1.05. Momentum favours further upside here.
In 2040, MXCT is projected to trade between $1.99 and $6.18, averaging $3.41 — a potential gain of +225% from today's $1.05. That is up +58% on the projected 2035 average. Buyers look set to stay in control over this stretch.
MaxCyte, Inc.'s 2050 outlook centres on $5.45, within a $2.72 to $10.94 range. That is up +60% on the projected 2040 average. That marks a +419% change versus current levels. Momentum favours further upside here.
Investing $1,000 in MXCT today (≈ 952.380952 MXCT) could be worth
$5,191.64
+$4,191.64 (+419%) by 2050 · US Dollar
Based on the average projected MXCT price of $5.45 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MXCTwould be worth at today's price.
$1,000 invested in MXCT on Jul 31, 2025 (≈ 485.436907 MXCT) would be worth
$509.71
-$490.29 (-49.0%) today · 0.51× · US Dollar
Based on a MXCT entry price of $2.06 vs. today's $1.05.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.08 | $972.22 | -2.8% |
| 1 month ago | $1.23 | $853.66 | -14.6% |
| 3 months ago | $0.88 | $1,193.18 | +19.3% |
| 6 months ago | $0.869 | $1,208.29 | +20.8% |
| 1 year ago | $2.06 | $509.71 | -49.0% |
| All time (5.0y) ago | $15.05 | $69.77 | -93.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MXCT forecast.
Our base-case forecast reaches $2.10 around 2033.
Implied market cap at $2.10: $224.96M
The multi-year forecast shows a gradual rise in the average price after 2026, turning more pronounced from 2030 onward. In 2030 the average price is forecast at $1.29 with a projected ROI of 26.4% and a bullish sentiment. The trajectory continues with 2031 at $1.36 (ROI 33.7%), 2032 at $1.79 (ROI 75.7%), and 2033 at $1.98 (ROI 94.6%), all characterized as bullish.
By 2040 the average forecast climbs to $2.98 with a high-trajectory ROI of 192.2% and a bullish outlook. In 2050 the forecasted average price reaches $4.56 with a maximum estimate of $9.76 and a bullish sentiment, implying a long-run upside of substantial magnitude (ROI 347.6%). These figures represent estimates and are not guarantees; actual results will vary with market conditions, execution, and external factors.
Tap a question to reveal the answer.
The forecasted average price in 2030 is $1.29, with a maximum of $2.03 and a minimum of $0.8873. The implied ROI is 26.4% and sentiment is BULLISH.
The forecast shows rising averages and positive ROIs from 2027 onward, with 2030 at 26.4% and 2050 at 347.6%, and bullish sentiment in later years. These are estimates and not guarantees, and investment outcomes depend on many factors.
Yes. The 2030 max is $2.03, and the 2040 max is $5.69, with the 2050 max at $9.76. These are potential upper bounds in the forecast and not guaranteed.
Current price: $1.02. Market cap: $109.26M.
RSI(14) is 30, indicating neutral momentum. The 50-day and 200-day SMAs are both $1.18, with a support level of $1.02 and a resistance level of $1.42. The 30-day price range is $0.7899 to $1.32.
MaxCyte, Inc. Community Discussion
0Share your MaxCyte, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.